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Accepted 20 July 2012AbstractAlzheimer disease (AD) is by far the most common cause of dementia globally. This neurodegenerative disorder of the brain is chronic and
progressive, characterized clinically by the deterioration in the key symptoms of behavioral and cognitive abilities. Treatment options for this
disease currently are limited. Deposition of amyloid-b and tau hyperphosphorylation are cardinal pathologic features of AD that lead to the
formation of neuronal plaques and neurofibrillary tangles, respectively. In addition to mounting research on herbal compounds for the treatment
of AD, curcuminoids and resveratrol appear to be beneficial as anti-AD agents. Curcuminoids (curcumin and demethoxycurcumin) and
resveratrol possess unique properties that make them especially worthy of further studies. This review article revisits and presents the current
research done on the potential of the curcuminoids curcumin and demethoxycurcumin and the polyphenolic compound resveratrol as anti-AD
compounds.
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Demographic ageing is a global process that denotes the
success of improved healthcare over the past years. Today,
human life expectancy is significantly longer resulting to
a much greater proportion of elderly people. Nevertheless,
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http://dx.doi.org/10.1016/j.tjog.2012.09.005documented that corollary to ageing there is also an increase in
cases of Alzheimer’s disease and other dementias in the senile
but modern society. It is the aim of this review paper to present
the benefits and potentials of curcumin, demethoxycurcumin
and resveratrol as a therapeutic agent for Alzheimer’s disease.
Alzheimer diseasedan emerging burden on society
The globally prevalent illness Alzheimer disease (AD) is
a genetically complex disorder that accounts for most cases of
dementia experienced by older people. It is a neurodegenera-
tive disorder affecting major brain areas including the cortex
and limbic system, and is characterized by progressive declinecs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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function [1]. AD often begins with symptoms such as short-
term memory loss and progresses with more widespread
cognitive and emotional dysfunction. The so-called late-onset
AD occurs after age 65 years. AD features ongoing deterio-
ration of the patient’s functioning, which results in substantial
and long-lasting disability over the approximate 7e10 years
from diagnosis to eventual death [2]. A diagnosis of AD is
correct when the disorder is not limited to the period of
delirium, is present for at least 6 months, and has no alter-
native explanation [3].
The health and social welfare of elderly people have long
been underprioritized in the public health policy of most
countries. The progressive mental deterioration in old age has
been recognized and described throughout history. However, it
was not until 1906 that a German physician, Alois Alzheimer,
identified a collection of brain cell abnormalities as a disease
[4]. He presented in his paper the results of postmortem
studies on his patient, a 51-year-old woman named Auguste D.
who had experienced a progressive presenile dementia [5], the
first case of AD ever documented. In Dr. Alzheimer’s paper,
the patient showed strong feelings of jealousy toward her
husband, followed by rapid memory impairment and disori-
entation in time and space. She then became bedridden and
incontinent. She died 4.5 years after the onset of the illness.
Her brain autopsy revealed an evenly affected atrophic brain
without microscopic foci. The larger cerebral vessels showed
arteriosclerotic changes [6]. Dr. Alzheimer also observed the
presence of usual deposits in the cortex that were refractory to
staining.
Dementia has contributed 11.2% of years lived with
disability in elderly people age 60 years and older; more than
stroke (9.5%), musculoskeletal disorders (8.9%), cardiovas-
cular disease (5.0%), and all forms of cancer (2.4%) as
reported in the global burden of diseases of the 2003 World
Health Report. Based on the 2005 Lancet study by Ferri et al
[7] on the global prevalence of dementia, 4.6 million new
cases of dementia are projected to be recorded each year,
with a rate of one case per 7 seconds, and the number of
people affected will double every 20 years to as high as 81.1
million by 2040. It was predicted that most people with
dementia will live in developing countries (60% in 2001,
rising to 71% by 2040). However, the rates of increase are not
uniform; thus, numbers in developed countries are forecasted
to increase by 100% between 2001 and 2040, but more than
300% in India, China, and their South Asian and Western
Pacific neighbors. In addition, there are currently an esti-
mated 18 million people worldwide in whom AD has been
diagnosed, according to the World Health Organization. In
2025, it is estimated that this figure will double to approxi-
mately 34 million [8]. Although people with dementia are
heavy consumers of health services, direct costs in developed
countries occur mostly from community and residential care.
Despite technologic advancements in medicine, research
revealed that most people currently living with dementia
have not received a formal diagnosis. In countries with high
income, only 20e50% of dementia cases are recognized andare documented during primary care. This treatment gap is
without a doubt much greater in low- and middle-income
countries, with one study in India suggesting 90% remain
unidentified [9]. If the current statistics are extrapolated to
other countries worldwide, it suggests that approximately 28
million of the 36 million people with dementia have not
received a diagnosis and therefore do not have access to the
treatment, care, and organized support that a formal diag-
nosis can provide. This situation clearly presents a major
concern, given that the world’s population is aging; new
cases of dementia and AD are steadily increasing. Therefore,
early diagnosis and intervention are important mechanisms
by which the treatment gap can be closed.
Amyloid bdthe culprit in AD pathology
In past years, important progress has been made in the
understanding of the pathogenic mechanisms of AD, and new
therapeutic drugs have become available that allowed the
underlying disease process to be treated directly. In this
respect, the “amyloid hypothesis” has become the dominant
theory in this field. It is believed that amyloid beta (Ab)
accumulation in plaques or as partial soluble filaments initiates
a pathologic cascade leading to tangle formation [10],
neuronal dysfunction, and possibly inflammation and oxida-
tive damage, with neurodegeneration and dementia as the final
outcome. The Ab is a 40e42 amino acid peptide that has
a b-pleated sheet amyloidogenic nature, as detected by Congo
red and thioflavin-S staining. The Ab peptides, which are
3e4 kDa in length, are the building blocks of both the amyloid
fibrils in neuritic plaques, in addition to the vascular deposits
that accumulate in the brains of AD patients. The Ab is
derived from the proteolytic processing of one or more
isoforms of the amyloid-b precursor protein (APP) [11].
Furthermore, the Ab can exist in two primary forms: as
a soluble peptide or in an aggregated state as insoluble
amyloid deposits in a beta-sheet conformation; this aggregated
state forms the basis of the senile plaques characteristic of AD.
Previous studies have shown the neurotrophic characteristic of
Ab at low dosages (1010 M to 108 M); nevertheless, at
higher doses (>107 M) the peptide becomes neurotoxic [12].
There are also some reports that the protofibrils of Ab, which
are metastable intermediates in amyloid fibril formation, may
be toxic [13]. The size of Ab oligomers is distributed over
a wide molecular weight range (from <10 kDa to >100 kDa),
with structural polymorphism in Ab oligomers of similar sizes.
The soluble Ab oligomers are found to be more cytotoxic than
fibrillar Ab aggregates in general and inhibit many critical
neuronal activities including long-term potentiation, a classic
model for synaptic plasticity and memory loss in vivo and in
culture [14,15]. Low-molecular-weight Ab oligomers found in
the soluble fractions of the human brain and amyloid plaque
extracts [16] were suggested to be the building blocks of larger
oligomers or insoluble amyloid fibrils [17,18]. The high
toxicity of low-molecular-weight Ab-oligomers is also sup-
ported by in vitro studies showing that Ab dimers are threefold
more toxic than monomers and that tetramers are 13-fold more
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these can form fibrillar aggregates that have properties similar
to those found in AD plaques in the brain. Lambert et al [14]
published the formation of small globular Ab oligomers
(approximately 5 nm in diameter) in Ham’s-F12 medium.
These globular oligomers were referred as Ab-derived diffusib
ligands. These molecules strongly bind with the dendritic
arbors of cultured neurons to cause neuronal death and the
blocking of long-term potentiations [14].
Upon reaching the critical concentration, with the Ab
aggregates forming insoluble amyloidogenic deposits, there is
then an observed general age-related increase in Ab genera-
tion by the neural cells [19]. Studies have shown that the
42-amino-acid form of the Ab is the more amyloidogenic of
the two forms of the peptide, and it manifests a greater
tendency to create insoluble deposits commonly seen in brains
affected by AD [20e22]. In certain familial AD, including
cases of APP mutation [23] and presenilin mutations [24],
there is an increase in the Ab42:Ab40, with the larger form of
the peptide acting as a potential “seed” for the deposition
of the amyloid peptide and plaque formation. The deposition
of the Ab appeared to be an early event in AD-associated
neurodegeneration, with this peptide acting as a seed for the
subsequent deposition of the Ab40 peptide.
Amyloid-b precursor proteinda multifunctional
molecule in the central nervous system
Although there are many components contained within the
neuritic plaques of the brain affected by AD, the APP has
a distinct role toward the pathogenesis of AD. The APP iso-
forms are Type I transmembrane sialoglycoproteins encoded
for by a single gene on chromosome 21 that contains 19 exons
[25]. The three primary APP isoforms are as follows: APP695,
APP751, and APP770. The APP is a multifunctional protein that
serves in both cell adhesion and neurite outgrowth. The APP
protein has been demonstrated to interact with a number of
elements of the extracellular matrix that include collagens I and
IV [26], laminin [27], fibronectin [28], heparan sulfate [29],
and some glycosaminoglycans [30]. APP has also been
proposed to play a role in the modulation of synaptic plasticity
[31]. This protein can also play a role in long-term potentiation
[32]. The soluble form of APP may also elicit both neuro-
trophic and neuroprotective properties. The APP acts as
a neuroprotective agent, stabilizing intracellular calcium levels
wherein the treatment of cells with APP resulted in rapid and
prolonged decrease in cellular Ca2þ [33]. The APP was able to
attenuate the toxic actions of the Ab peptide by overcoming the
Ab-associated elevation of free intracellular Ca2þ levels with
the associated induction of free radical species [34]. As a neu-
rotrophic agent, APP stimulates neuronal cell differentiation
and neurite outgrowth. Transfection of an APP-null neural cell
with APP complementary DNA (cDNA) resulted in an
increased neurite outgrowth. The binding of a larger peptide
(Ala319 to Met335) to cell membrane preparation is both satu-
rable and specific, suggesting that soluble APPs (APPs)
mediates its effect by a receptor-mediated mechanism [35].With regard to APP protein processing, two alternate
pathways are known. The primary pathway produces APP
after the cleavage at Lys16 within the Ab region of the protein
by the enzyme, alpha (a)-secretase. The alternative pathway
can be through the cleavage of the APP protein by the b- and
g-secretase to generate the 40e42 amino acid Ab peptide. The
major species of the Ab produced at normal circumstances is
the 40 amino acid form (Ab40). However, Ab42 was found to
be increased in AD and was observed to be more amyloido-
genic and acts as a seed for amyloid deposition [36]. The
pathway by which APP is processed can be influenced by
a multitude of factors that may be extracellular or intracellular.
In addition, the processing mechanisms could be cell-, tissue-,
or species-specific. There is also an increasing number of
evidence that the carboxy-terminal fragment of the APP may
also exhibit neurotoxicity in addition to Ab [37]. The toxic
fragment was identified as a 100-amino-acid C-terminal
fragment (C100 protein). This fragment inhibits the Mg2þ/
Ca2þ-adenosine triphosphatase within the endoplasmic retic-
ulum and also the Naþ/Ca2þ exchanger. This in turn
compromises the ability of the cells to sequester Ca2þ within
the endoplasmic reticulum, thereby raising the level of the
intracellular Ca2þ [38,39]. The C100 appears to be a more
potent neurotoxin than the Ab [37]. It also exhibits neurotoxic
actions in vivo, and transgenic mice overexpressing the peptide
displays some neuropathologic features characteristic of the
AD brain [40,41]. The processing of the APP is one critical
event in the pathogenesis of AD; these processes can be
modulated by different factors that include neurotransmitter
receptors and activation of a multitude of second messenger
systems. These can then provide therapeutic potentials for the
action of anti-AD agents that may elicit certain pharmacologic
action toward the increased secretion of soluble APPs and
diminished production of the amyloidogenic Ab peptide.
Tau proteindits role in AD progression
Tau (t) is a major microtubule-associated protein that was
almost simultaneously discovered in the United States and
Europe [42e44]. It was first identified as a “factor essential for
microtubule assembly” from purified tubulin. The t protein is
abundantly expressed in both the peripheral and the central
nervous systems, [45] although low levels of t protein are also
present in the oligodendrocytes and astrocytes [46]. Tau
undergoes a developmentally regulated phosphorylation
having 38 phosphorylation sites [47]. The fetal brain as well as
the pathologic brain has highly phosphorylated t if compared
with the normal adult brain [48]. The cDNA for t was first
isolated from the mouse brain expression library [49], then it
was cloned from other species such as goat [50], chicken [51],
bovine [52] and human [53,54].
The human t gene is located on the human chromosome
17q21 and has at least 16 exons. To date, at least six different
known major t protein isoforms are brought about by
messenger RNA (mRNA) alternative splicing [55] involving
exons 2, 3, and 10, whereas exon 4A is only transcribed in
the peripheral nervous system [56,57]. The expressed protein
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100 kDa. The six isoforms consist of 352e441 amino acids
with apparent molecular weight between approximately
37e46 kDa and pI values of 6.85e9.46 [58]. In some articles,
the apparent molecular weights of the t isoforms ranges from
60 kDa to 74 kDa [59] The t-isoform’s structure becomes
more complex due to various posttranslational modifications
such as nitration, ubiquitination, glycosylation, phosphory-
lation, and truncation. Structurally, t protein is hydrophilic
and appears as a random coiled protein as analyzed by
circular dichroism. The brain t isoforms have two large
domains: the projection domain, which comprises the amino
acid terminal two-thirds of the molecule, and the
microtubule-binding domain, which contains the carboxy-
terminal third of the molecule. Furthermore, the projection
domain can be divided into two regions: the amino terminal
region with a high proportion of acidic residues and the
proline-rich region. The microtubule binding domain can
also be divided into the basic, true tubulin-binding region and
the acidic carboxy-terminal.
AD is the best-known “tauopathy” because it is charac-
terized by the aggregation of the abnormally phosphorylated
t protein. It is apparent that during normal development and
as mentioned earlier, the t protein undergoes various post-
translational modifications. As a result, an increased amount
of the modified t has been associated with a large number of
neurodegenerative disorders. In the process of aggregation to
form paired helical filaments (PHFs), there should be
a reduced affinity of the t protein for the microtubules to
accompany the release of t into a soluble form. Dissociation
of t from the microtubule that may have been a result of the
phosphorylation at some sites in the t protein bring about
microtubule destabilization. The resultant soluble t protein
becomes an ideal target for posttranslational modifications
and may change directly or indirectly the conformation of the
t protein, thereby inducing t dimerization in an antiparallel
manner. Subsequently, the stable t dimers then form t
oligomers and the aggregation process continues, therefore,
constituting the subunits of filament called protomers. Coil-
ing of two protomers with each other then forms PHFs. These
PHFs then mature and assemble to form neurofibrillary
tangles (NFTs). The NFTs are intraneuronal aggregates of
the abnormally phosphorylated t. NFTs correlate with the
degree of dementia in AD. Currently, the molecular and
cellular mechanisms that could explain the formation of t
lesions remain elusive. These lesions appeared to be
controversial as to whether it could be considered a primary
etiologic factor of the disease. Phosphorylation of t is by far
the most common and well-studied posttranslational modi-
fication associated with AD. It was observed that there is an
obvious increased level of hyperphosphorylated t in brains of
AD patients that is three to four times higher than that found
in normal adult brain [60,61] because normally a t phos-
phoprotein contains one to three molecules of phosphate
ðPO43Þ per molecule of t. Protein phosphorylation involves
the addition of a phosphate group via esterification on the
following amino acid residues: serine (S), threonine (T), andtyrosine (Y). There are 85 putative phosphorylation sites on
t: 45 (53%) are on serines; 35 (41%) are on threonines; and 5
(6%) are on tyrosines. Phosphorylation is also modulated by
various kinases and phosphatases. Therefore, hyper-
phosphorylation is a consequence of a dysregulation of the
kinases and phosphatases. Currently there are more than 10
serine/threonine protein kinases known to phosphorylate t
protein in vitro. These kinases are categorized into two
according to the motif specificity: proline-directed and
nonproline-directed protein kinases. The proline-directed
protein kinases include extracellular signal-regulated kinase
1/2 (erk-1/2), cell division cycle 2 kinase (cdc 2), cyclin-
dependent kinase 2 (cdk 2), and the cdk 5. Although
proline is not needed strictly in the phosphorylation of t
protein by Glycogen synthase-3 (GSK-3), still the presence
of proline improves the phosphorylation efficiency.
The nonproline-directed kinases are calcium- and
calmodulin-dependent protein kinase II, PKA protein kinase
(PKC), casein kinase I, casein kinase II and p110MARK.
The t protein may also undergo prolyl isomerization,
a reaction that allows the rearrangement of disulfide bonds in
proteins. This involves the modification of the conformation of
the protein of interest from cis to trans conformation and vice
versa. The change in the conformation of the t protein from
cis to trans allows a shift of the peptide chain in space,
allowing them to be more available for the action of phos-
phatases. Prolyl isomerization of t can be achieved by the aid
of the enzyme, peptidylprolyl isomerase Pin-1 (peptidylprolyl
cis/trans isomerase NIMA interacting-1; NIMA: never in
mitosis gene A) [62]. Pin-1 interacts with t to prevent its
pathologic accumulation [63]. Also, t nitration proceeds by
the addition of nitrogen dioxide on tyrosines of the molecule
that occurs particularly at four sites Y18, [64] Y29, Y197, and
Y394 [65]. This reaction was observed to be involved in the
aggregation of the t protein [66]. Polyamination is a reaction
catalyzed by transglutaminases involving a glutamine residue
as an acyl donor and a lysine as an acyl acceptor. The reaction
results to the formation of g-glutamyl- 3-lysine isopeptide bond
and provokes protein cross-linking [67]. The primary donor
site is Q424 and the principal acceptor is in the region between
residues K163 and K240, [68] thereby linking t polyamination
to the NFT formation process. Oxidation can also occur on the
t protein that leads to the assembly of the paired helical
filaments [69,70]; it occurs at amino acid residue C322
localized in the R3 domain of the microtubule-binding domain
(MDB) region. The C322 is linked to the formation of tau
lesions.
To date, it is still difficult to ascertain which among the
previously described post-translational modifications is pref-
erentially involved in t pathology and AD. Most certainly, an
orchestration among several t modifications is required for t
aggregation into NFTs. Therefore, studying t regulation at
transcription and translation levels is of high significance in
our understanding of the physiologic role of t and its
involvement in the development of AD. This is also particu-
larly important in identifying compounds that are of thera-
peutic value for AD.
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Scientists around the globe have been trying for decades to
treat and put an end to the pathologic symptoms of AD that
deprive elderly persons of their intellect, but have had limited
success. Despite these efforts, only four Food and Drug
Administration-approved drugs are currently commercially
available in the United States to treat AD pathology [71]. These
drugs mainly target cholinergic functions associated with AD,
leavingmost other potential AD targets almost unaffected by the
treatment. As a result, there is an urgent need for developing
drugs based on multiple pathomechanisms of AD. The enor-
mous diversity of functions in natural compounds extracted and
isolated from either plant or marine sources may provide a new
generation of drugs for AD therapy and management [72,73].
Plant-derived drugs are popular because the public believes that
herbs are naturally safer than synthetic drugs. These beliefs may
account for the sudden increase in the use of herbal treatment
during the last decades [74]. This review also presents an update
on the current researches undertaken on curcumin, demethox-
ycurcumin, and resveratrol regarding their potential for use in
the treatment of AD.CurcuminoidsCurcumin (Fig. 1) is a bright yellow powder that was first
identified in 1910 [75]. This compound is also known as
deferuloylmethane, natural yellow 3 and (1E,6E )-1,7-bis(4-
hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione. It has
a formula weight equivalent to 368.38 g mole1. This
substance was isolated from the plant Curcuma longa or
turmeric that is commonly used for culinary purposes. This
substance possesses several functional groups wherein the
planar aromatic ring systems are attached to a,b-unsaturated
carbonyl groups. The diketones generate stable enols
that could be easily deprotonated to form enolates. The
a,b-unsaturated group can undergo nucleophilic addition and
Michael reaction. Curcumin has been shown to possess a wide
range of pharmacologic activities, including anti-inflammatory
[76,77], antioxidant [78], anticancer [79], wound healing [80],
and antimicrobial effects. Curcumin has been shown to exhibit
activity against various neurologic diseases, including AD
[81], multiple sclerosis [82], Parkinson disease [83], epilepsy
[84], cerebral injury [85], age-associated neurodegeneration
[86], schizophrenia [87], spongiform encephalopathies
(CreutzfeldteJakob disease) [88], neuropathic pain [89], and
depression [90].
The oxidation process occurs mostly in the brain and it
consumes 20% of the body’s oxygen despite accounting for
only 2% of the total body weight. With normal aging, the brainOO
OH OH
O
CH3
O
CH3
Fig. 1. Structural formula of curcumin.accumulates metals ions such as iron (Fe), zinc (Zn), and
copper (Cu). Thus, the brain requires copious amounts of
antioxidants that control and prevent the damaging effects of
reactive oxygen species generated via the Fenton reaction
concening redox-active metal-ion reduction and activation of
molecular oxygen [91]. In AD, copper ions are also involved
in the progression of the disease, and copper uptake is regu-
lated by the APP. Copper has high affinity to both APP and
Ab; Huang et al [92] recently reported that curcumin may play
a dual role in protecting the rat cortical neuron against the
Cu(II)-induced oxidative damage. Low dosages of curcumin
(i.e. 1, 5, and 10 mM) were able to depress oxidative stress
levels exacerbated by Cu(II); however, high dosage (>10 mM)
of curcumin failed to decrease the Cu(II)-induced oxidative
stress [92]. It was found that curcumin and its structural
analogs, demethoxycurcumin and bisdemethoxycurcumin, can
protect PC12 rat pheochromocytoma and normal human
umbilical vein endothelial cells from Ab-induced oxidative
stress, and that these compounds were better antioxidants than
a-tocopherol [93]. Zhang et al [94] in 2010 investigated the
effect of curcumin on the metabolism of Ab and APP in
various cell lines including rat neuroblastoma cells over-
expressing human APP751. Curcumin significantly increased
the levels of matured APP at low concentrations (5 and
10 mM) and there was an observed decrease in the level of
matured APP at 15 and 20 mM. As a result, curcumin treat-
ment markedly increased the ratio of matured APP and
immature APP at lower concentrations and again the ratio was
decreased significantly at higher concentrations of curcumin
[94]. In a study by Ishrat et al [95], supplementation of cur-
cumin on intracerebroventricular-streptozotocin infused rats
significantly alleviated cognitive deficiencies resulted from
intracerebroventricular-streptozotocin infusion. Curcumin
further prevented oxidative damage to the hippocampus and
cerebral cortex as ascertained through the following
biomarkers: (1) increased 4-hydroxynonenal, malondialde-
hyde, thiobarbituric reactive substances, hydrogen peroxide,
protein carbonyl and oxidized glutathione; and (2) diminished
amounts of reduced glutathione and enzymes glutathione
peroxidase and glutathione reductase [95]. The potential
reversal of the intracerebroventricular-streptozotocin-induced
alterations in cognitive behavioral and biochemical parame-
ters suggests that addition of curcumin as part of our diet may
help reduce the incidence of age-related sporadic dementia of
Alzheimer type.
In 2005, Yang et al [96] showed that curcumin could inhibit
aggregated as well as disaggregated Ab40. In this regard,
curcumin was seen to be a better Ab40 aggregation inhibitor
than ibuprofen or naproxen. In this regard, studies by Yana-
sigawa et al [97] on derivatization of curcumin aiming to
increase the anti-Ab aggregation activity of curcumin revealed
that the curcumin derivatives have high levels of binding to Ab
aggregates and not the Ab monomers. In the same study, the
enol form was more predominant among the curcumin deriv-
atives that interacted with the Ab aggregates. This may be
because compounds may only be able to bind with Ab
aggregates. In addition, the compound needs to be coplanar
OO
OH OH
O
CH3
Fig. 2. Structural formula of demethoxycurcumin.
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carbon chains also known as the Goldilocks model [98]. The
curcumin derivatives used in the study by Yanasigawa et al
[97] conformed with the Goldilocks model for the compound,
and maintained the coplanarity and the presence of the
extended double bond conjugation between the two phenyl
rings which gave the strong binding affinity of curcumin to the
Ab aggregates. The microtubule-associated protein 2 (MAP2)
is a neuronal cytoskeletal component that plays an important
role in the preservation of cellular architecture and internal
organization, with certain involvement in the determination of
cellular shape, in cell division, and cellular processes [99].
Changes in the architectural framework of the cytoskeleton
bring forth malfunctions of the nerve cells in brain tissues of
patients with AD. In a study by Xiao et al [100], it was re-
ported that chemically synthesized curcumin and its deriva-
tives can increase the viability of human neuroblastoma SK-N-
SH cells after Ab1-42 insult. Treatment of SH-N-SK cells with
curcumin and its derivatives resulted in an increase expression
of the MAP2. The upregulation of the MAP2 protein may be
associated with the reorganization of the cytoskeleton during
the degeneration of neuronal cells in AD and this implied that
curcumin may have played a pivotal role in improving
abnormal neuronal cell morphology by being able to restore
normal physiology within the cell. In addition, the molecular
structure of curcumin and its derivatives may also be respon-
sible for their neuroprotective function. The important role of
b-diketone moiety, 4-hydroxyl group on the benzene ring
might be a key group of resistance to Ab neurotoxicity,
whereas 3-methoxy could indirectly affect the beneficial effect
of curcumin derivatives related to suppressing 4-hydroxyl
[101]. It was also described that the hydrogen atom donation
from the b-diketone part of the lipid alkyl or the lipid peroxyl
radical is the potentially more important antioxidant action of
curcumin [93]. Recently, solid-state nuclear magnetic reso-
nance studies demonstrated that curcumin can interact with the
12th and 17th to 21st amino acid residues of the Ab42 fibrils.
Furthermore, based on the clear cross-peaks between carbons
adjacent to methoxy and/or hydroxy groups revealed by C13 to
C13 2D solid-state nuclear magnetic resonance experiments,
the presence of the functional groups on the aromatic rings
plays an important role in the anti-Ab aggregative property of
curcumin [102]. In a study conducted by Liu et al [103],
curcumin exhibited the most potent activity in the restraint of
the production of Ab42 in swap HEK293 cells followed by
demethoxycurcumin and bisdemethoxycurcumin. Their group
also found that curcumin but not other curcuminoids was able
to decrease the APP protein expression, suggesting that the
antiamyloidogenic property of curcumin can be attributed to
its effect on the APP metabolism.
Demethoxycurcumin (Fig. 2) is a structural analog of
curcumin less one methoxy group and is also isolated from
the plant C. longa. It comes as orange powder with a formula
weight equal to 338.35 g mole1. Its IUPAC name is
(1E,6E )-1-(4-hydroxy3-methoxyphenyl)-7-(4-hydroxyphenyl)
hepta-1,6-diene-3,5-dione and may commonly be referred
to as desmethoxycurcumin, monodemethoxycurcumin, orparahydroxycurcumin. Several articles have been published
associating members of the curcuminoid family with AD.
Listed herein are some of the results gathered by researchers
implicating demethoxycurcumin with AD. b-Amyloid (Ab)
induced oxidative stress is a well-established pathway of
neuronal cell death in AD. The curcuminoids curcumin,
demethoxycurcumin, and bisdemethoxycurcumin, were
observed to protect PC12 rat pheochromocytoma and normal
human umbilical vein endothelial cells from Ab42 insult, as
measured by MTT assay. The ED50 values of curcumin,
demethoxycurcumin, and bisdemethoxycurcumin toward
PC12 and human umbilical vein endothelial cells were
7.1  0.3, 4.7  0.1, 3.5  0.2 mg/mL and 6.8  0.4,
4.2  0.3, and 3.0  0.3 mg/mL, respectively. These
compounds were found to be better antioxidants than a-
tocopherol as determined by DPPH radical trapping experi-
ment. a-Tocopherol did not protect the cells from Ab (1e42)
insult even at >50 mg/mL concentration. The results suggested
that these compounds protected the cells from Ab42 insult
through antioxidant pathway [104]. Ahmed and Gilani [105]
in 2009 reported on their conducted experiments on curcu-
minoids including demethoxycurcumin for anti-
acetylcholinesterase (AChE) activity in vitro and ex vivo. It
was observed that, in vitro, demethoxycurcumin has
a marginal effect on AChE inhibition compared with bisde-
methoxycurcumin and curcumin has the lowest activity.
Ex vivo, both demethoxycurcumin and bisdemethoxycurcumin
were able to show anti-AChE activity [105]. Investigation on
the effects of curcuminoid mixture and individual constituents
on spatial learning and memory in an Ab peptide-infused rat
model of AD and on the expression of post-synaptic density
protein-95 (PSD-95), synaptophysin, and Caþ2/calmodulin-
dependent protein kinase IV (camkIV) were carried out.
Curcuminoid mixture exhibited a memory-enhancing effect in
rats displaying AD-like neuronal loss marginally at 30 mg/kg,
whereas individual components were effective at 3e30 mg/kg
dosages. A short period of treatment with test compounds
showed that the curcuminoid mixture and bisdemethox-
ycurcumin increased PSD-95 expression in the hippocampus
at 3e30 mg/kg. The maximum effect was observed at a low
dose of 3 mg/kg with respective values of 470.5 and 587.9%.
However, after a longer treatment time, both demethox-
ycurcumin and curcumin also increased PSD-95 level up to
331.7 and 226.2%, respectively, at 30 mg/kg. Meanwhile, their
effect on synaptophysin in the hippocampus after the longer
duration treatment was studied. The curcuminoid mixture and
all three individual components increased synaptophysin
expression. Among these, demethoxycurcumin was the most
effective, showing a 350.1% increase ( p < 0.01) at 30 mg/kg
compared with the neurotoxin group. The compounds’ effect
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mined. Only demethoxycurcumin increased camkIV levels to
421.2% at a concentration of 30 mg/kg. These compounds
salvaged PSD-95, synaptophysin, and camkIV at the expres-
sion levels in the hippocampus in the rat AD model, sug-
gesting multiple target sites giving out the potential of
curcuminoids in enhancing the spatial memory and disease
progression in AD. Recently, the effect of a curcuminoid
mixture and its individual components on inflammatory and
apoptotic genes expression in AD using an Ab þ ibotenic
acid-infused rat model was explored. Five days after treatment
with demethoxycurcumin, the amounts of hippocampal IL-1b
were decreased to 118.54  47.48 and 136.67  31.96%,
respectively, at 30 mg/kg and 10 mg/kg, compared with the
amyloid treated group (373.99  15.28%). Also, 5 days
treatment with the curcuminoid mixture and demethox-
ycurcumin effectively decreased the levels of glial fibrillary
acidic protein, a specific marker for astrocytes hyperactivity,
often elevated in inflammatory conditions and AD, in the
hippocampus. The curcuminoid mixture and bisdemethox-
ycurcumin effectively decreased caspase-3 level in the
hippocampus after 20 days of treatment, where bisdemethox-
ycurcumin showed a maximal rescuing effect that is
92.35  3.07% at a concentration of 3 mg/kg. Furthermore,
the curcuminoid mixture also at 30 mg/kg decreased hippo-
campal Fas ligand levels to 70.56  3.36% after a 5-day
treatment and 19.01  2.03% after 20 days. Measurement of
the amount Fas receptor, demethoxycurcumin decreased the
levels after 5 days of treatment, with all three doses showing
a maximum effect (189.76  15.01%) at 10 mg/kg. Individual
compound was efficient 20 days posttreatment in plummeting
Fas receptor levels in the hippocampus. This study demon-
strated the important outcomes of curcuminoids administration
on gene expressions.ResveratrolResveratrol (Fig. 3) was first reported in 1939 by a
Japanese researcher, Dr. Michio Takaoka, after it was
extracted, purified, and isolated from a poisonous but medic-
inal herb, Veratrum album var. grandiflorum [106]. Resveratrol
is a stilbenoid, a derivative of stilbene, that is also known as
3,4,50-trihydroxystilbene. It has a molecular weight equivalent
to 228.24 g mole1. This compound appears as white powder
with slight yellow tinge. It exists in nature as two geometric
isomers, cis- and trans-resveratrol. The trans-resveratrol is
the more biologically active isomer. However, exposure to
ultraviolet light of the trans-resveratrol leads to its conversion
to its inactive form, cis-resveratrol [107]. In grapes,OH
OH
OH
Fig. 3. Structural formula of resveratrol.trans-resveratrol is a phytoalexin produced against the growth
of fungal pathogens such as Botrytis cinerea [108]. Also, most
of this compound is found in the skin and seed of the grape’s
fruit (Vitis vinifera) [109]. An epidemiologic association
between the common red wine and a low occurrence of
cardiovascular diseases led to the beginning of what was
referred to as the “French Paradox”, coined by Serge Renaud,
a scientist from Bordeaux University, despite the saturated fat-
rich diet consumed by the French people. Furthermore,
resveratrol attracted greater attention when its presence in red
wine was suggested as an explanation for the cardioprotective
effects of wine. Wine and grape extract have been shown to
reduce platelet aggregation, uphold vasorelaxation, prevent
atherosclerosis, decrease lipid peroxidation, and ameliorate
serum cholesterol and triglyceride concentrations [110].
Because resveratrol has shown unprecedented promise for
the development of new drugs, intense efforts are being made
to understand its use in promoting healthy aging, longevity,
and neuronal protection. Reports were made telling the
significance of resveratrol as a neuroprotective agent. To date,
it is still not clear how resveratrol may be essential in neuronal
protection. Scientists currently still have to prove whether
resveratrol takes its action through the traditionally known
antioxidant properties that could be more effective than the
cytoplasmic signal transduction pathways, or whether it may
act through direct modulation of neuronal functions. Studies
strongly implicate sirtuins in neuronal protection, and have
also shown that calorie-restriction types and calorie-restriction
mimetics can elevate sirtuin production in the human brain. As
mentioned previously, resveratrol can act as a calorie-
restriction mimetic, making it a good neuroprotective candi-
date compound acting via the sirtuin pathway [110]. Sirtuins,
particularly SIRT-1, may play an important role in protecting
neurons from the devastating effects of reactive oxygen
species, peroxides, nitric oxide, b-amyloid peptides, and other
intracellular and extracellular insults that could be present in
the brain with AD. Resveratrol-induced SIRT-1 over-
expression has been found to deacetylate and suppress the
activity of p53 in neurons, thus preventing apoptotic death of
neurons. In addition to this finding, the apoptotic activities of
the FOXO proteins were also inhibited by resveratrol-induced
SIRT-1 expression [111]. FOXOs has functional similarities
and takes part in the cross-talk with p53. In another study, it
was observed that resveratrol-induced SIRT-1 inhibited the
signaling pathway of the nuclear factor kappa B (NF-kB) in
microglia and astrocytes resulting in the protection against
Ab-induced toxicity [112]. Soluble forms of Ab can accu-
mulate in the endothelial cells of the blood vessels of the brain
with AD that ultimately inhibits the endothelial nitric oxide
synthase (eNOS) activity. This phenomenon later causes toxic
effects on nitric oxide functions such as Ca2þ dyshomeostasis
[113]. This study suggests that in brains with AD, resveratrol
may increase eNOS, modulate the expression of SIRT-1, and
affect other cellular metabolic functions. Resveratrol also
protects both nerves and blood vessels against Ab insults.
Moreover, amyloid peptides trigger the activation by acting
with a number of Toll-like receptors (TLRs) including TLR4.
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prevent the activation of murine RAW 264.7 macrophages
(mouse leukaemic monocyte macrophage cell line) and the
microglial BV-2 cells treated with the TLR4 ligand, lipo-
polysaccharide. The activation may be due to the reason that
resveratrol may have acted upstream during the activation
cascades interfering in the TLR4 oligomerization after the
stimulation of the receptors. In this same study, resveratrol was
demonstrated to hinder the proinflammatory events as conse-
quences of the presence of the fibrillar Ab on macrophages by
effectively inhibiting the effect of Ab on the phosphorylation
of IkB, activation of STAT1 and STAT3, and on the secretion
of tumor necrosis factor-a and interleukin-6 [114].
In transgenic APPmice experiments, excessive and persistent
reactive oxygen species production caused by the interaction of
Ab with Ab-induced alcohol dehydrogenase may result in
oxidative damage to mitochondrial and cellular biomolecules,
resulting in a shut-down of mitochondrial energy production
[115]. Finally, resveratrol had longbeen considered as a powerful
antioxidant, and evidence has indicated the potential of resver-
atrol as a neuro-protecting agent. In PC12 cells, resveratrol was
able to protect cells from Ab25-35-induced toxicity; it was also
able to attenuate apoptotic cell death, reduce changes in mito-
chondrial potential and inhibited accumulation of reactive
oxygen species [116]. Another important finding byMarambaud
et al [117] regarding the neuroprotective role of resveratrol is its
ability to interact with the ubiquitin proteosome system (UPS)
by affecting the proteosome-mediated degradation of Ab
through a mechanism that does not directly increase the activity
of the proteosome. The UPS is one of the main cellular, protein
quality controlmechanisms that enzymatically labels, transports,
and eventually degrades the misprocessed and misfolded
proteins [118]. It also controls all the metabolic reactions of
the components of APP. Unfortunately it has been found that
accumulation ofAb causes the reduction of the UPS. Recently, it
has been demonstrated that resveratrol was cytoprotective in
human neuroblastoma cells by exerting its role not through the
inhibition of b-amyloid aggregation but rather on its scavenging
abilities from the toxic effect of the accumulation of Ab and
Ab-metal complexes (Ab-Fe, Ab-Cu, Ab-Zn, and Ab-Al).
Resveratrol at a concentration of 15 mM acted as a reactive
oxygen species scavenger against those generated by Ab-Fe,
Ab-Cu, Ab-Zn complexes, thereby reducing their toxicity;
however, resveratrol is not sufficient to fully block the toxicity
induced by metal complexes [119]. Furthermore, it was
previously reported in an in vivo experiment that 2% resver-
atrol did not alter the holoAPP, aC-terminal (C83), and b-
terminal fragments (C99) when it was given ad libitum to
transgenic APP695 mice, Tg19959 [120].
The poor bioavailability of resveratrol limits its potential
for use in the treatment of AD because (1) polyphenols such as
resveratrol undergo extensive biochemical reactions including
oxidation, reduction, hydrolyses, glucuronic acid, sulfate, and
methyl conjugation immediately after ingestion, and (2) there
is a considerable person-to-person variability in drug absorp-
tion and metabolic process [109]. However, it is presumed that
the circulating form of resveratrol in the human body, thoughtto modulate numerous cellular and biochemical effects, is
predominantly the modified metabolite and not the aglycone.
This finding is true because the total recovery of glucuronic
acid and sulfates conjugated with resveratrol in human urine
and feces were about 71e98% through oral routes and
54e91% via the intravenous route [121].
Conclusion
AD is an incapacitating disease that deprives elderly indi-
viduals of their will and intellect. Apart from the diverse
biologic qualities such as anti-inflammatory, antioxidant, anti-
cancer, wound-healing enhancer, antimicrobial, and antiaging
shown by curcumin, demethoxycurcumin, and resveratrol,
these compounds had also found their niche in the anti-
AD research. Researchers considered curcumin, demethox-
ycurcumin and resveratrol as possible anti-AD compounds due
to their ability to prevent the aggregation of amyloid-
b peptides. For many of the pharmacologic activities including
the anti-AD activities that have been reported on curcumin,
demethoxycurcumin, and resveratrol, clinical data are very
limited. Clinical efficiency and potential toxicity of these
compounds in larger trials requires further evaluation before
recommendation regarding their use for AD treatment.
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